Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study

[1]  M. R. Hassett,et al.  saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern , 2023, Nature communications.

[2]  D. Barouch.  Covid-19 Vaccines — Immunity, Variants, Boosters , 2022, The New England journal of medicine.

[3]  Senthil Kumar Manoharan,et al.  Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials , 2022, eBioMedicine.

[4]  O. Watson,et al.  Global impact of the first year of COVID-19 vaccination: a mathematical modelling study , 2022, The Lancet Infectious Diseases.

[5]  Liyuan Liu,et al.  Antibody evasion properties of SARS-CoV-2 Omicron sublineages , 2022, Nature.

[6]  S. Luo,et al.  The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies , 2022, Journal of Immunological Methods.

[7]  J. Mascola,et al.  SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination , 2022, The New England journal of medicine.

[8]  Liyuan Liu,et al.  Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.

[9]  W. Blackwelder,et al.  Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial , 2021, The Lancet.

[10]  R. Baric,et al.  Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines , 2021, The New England journal of medicine.

[11]  Aaron M. Rosenfeld,et al.  mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern , 2021, Science.

[12]  C. Mcevoy,et al.  Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine , 2021, The New England journal of medicine.

[13]  E. Walsh,et al.  SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 , 2021, The New England journal of medicine.

[14]  J. Mascola,et al.  Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.

[15]  E. Wherry,et al.  Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination , 2021, Immunity.

[16]  A. Yılmaz,et al.  Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey , 2021, The Lancet.

[17]  P. Kalra,et al.  Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine , 2021, The New England journal of medicine.

[18]  S. McCormack,et al.  Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial , 2021, eClinicalMedicine.

[19]  E. Moriishi,et al.  OMIP 075: A 22‐color panel for the measurement of antigen‐specific T‐cell responses in human and nonhuman primates , 2021, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[20]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[21]  H. Schuitemaker,et al.  Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine , 2021, The New England journal of medicine.

[22]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[23]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[24]  P. Dormitzer,et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[25]  R. Baric,et al.  Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.

[26]  M. Beltramello,et al.  Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.

[27]  V. Shinde,et al.  Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine , 2020, The New England journal of medicine.

[28]  J. Mascola,et al.  An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.

[29]  U. Şahin,et al.  Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  N. Hayashi,et al.  Replication-Competent Recombinant Vesicular Stomatitis Virus Encoding Hepatitis C Virus Envelope Proteins , 2007, Journal of Virology.

[31]  K. Ishii,et al.  Characterization of pseudotype VSV possessing HCV envelope proteins. , 2001, Virology.

[32]  R. Johnston,et al.  Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. , 1997, Virology.